시장보고서

상품코드

1780283

처방약 시장 규모와 예측(2021-2031년) : 세계 및 지역 점유율, 동향, 성장 기회 분석 리포트 - 제품 유형, 약제 유형, 치료 영역, 투여 경로, 유통 채널, 지역

Prescription Drugs Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Product Type, Drug Type, Therapeutic Area, Route Of Administration, Distribution Channel, and Geography

발행일: 2025년 07월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 329 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당사의 최신 보고서 "2031년까지 처방약 시장 예측 - 세계 분석 : 제품 유형별, 약물 유형별, 투여 경로별, 치료 영역별, 유통 채널별"에 따르면 2024년 1조 4,407억 9,000만 달러에서 2031년에는 2조 3,501억 2,000만 달러에 달할 것으로 예측됩니다. 에 도달할 것으로 예상되며, 2025-2031년 연평균 복합 성장률(CAGR) 7.3%를 보일 것으로 예측됩니다. 처방약 시장의 성장은 만성질환의 확산과 혁신적이고 특수한 의약품의 개발 및 채택 증가에 기인합니다.

처방약은 법적으로 자격을 갖춘 의료 전문가의 의료용 처방이 필요한 의약품을 말합니다. 인체에 심각한 영향을 미치거나, 안전에 대한 감시가 필요하거나, 오남용의 가능성이 있으므로 규제를 받고 있습니다.

북미 처방약 시장은 미국, 캐나다, 멕시코로 구분됩니다. 북미는 세계 시장에서 큰 비중을 차지할 것으로 보입니다. 그 주요 요인 중 하나는 이 지역의 고령화입니다. 베이비붐 세대가 고령화되면서 당뇨병, 심혈관 질환, 암 등 만성질환의 유병률이 높아져 처방약에 대한 수요가 증가하고 있습니다.

제약 연구와 생명공학의 발전도 중요한 역할을 하고 있습니다. 생물제제 및 맞춤형 의료를 포함한 의약품 개발의 혁신은 치료의 선택권을 넓히고 효능과 안전성을 향상시켰습니다. 이전에는 치료할 수 없었던 질병에 대한 새로운 치료법의 도입은 시장 성장을 더욱 촉진하고 있습니다.

또한 의료시설, 보험, 의약품 유통망에 대한 막대한 투자로 지원되는 북미의 강력한 헬스케어 인프라도 큰 기여를 하고 있습니다. 헬스케어 서비스의 보급과 질병 관리에 대한 환자들의 인식이 높아지면서 처방약의 소비가 증가하고 있습니다. 또한 미국 식품의약국(FDA)과 같은 규제 당국의 지원으로 혁신적인 의약품의 신속한 승인 절차가 촉진되어 빠른 시장 진입이 가능해졌습니다. 또한 미국의 '의료비 부담 적정화법(Affordable Care Act)'과 같은 의료보험 적용 범위 확대를 위한 정부의 구상으로 인해 더 많은 사람들이 처방약에 대한 접근성이 증가하고 있습니다.

또한 생활습관병 증가와 정신질환의 유병률 증가는 치료제에 대한 지속적인 수요를 창출하고 있습니다. COVID-19 팬데믹은 의약품 개입의 중요성을 강조하고 의약품 개발 및 유통에 대한 투자를 가속화했습니다.

북미에서는 미국이 처방약 시장에서 큰 비중을 차지하고 있습니다. 암, 심장병, 당뇨병과 같은 만성질환이 처방약 수요 증가에 기여하고 있습니다. 심장병은 여전히 미국의 주요 사망 원인으로 매년 100만 명에 가까운 미국인이 심혈관 질환(CVD)으로 사망하고 있습니다. 미국심장협회에 따르면 미국 성인의 약 절반이 CVD를 앓고 있으며, 2035년까지 심부전을 앓는 성인의 수가 증가할 것으로 예상되고 있습니다. 2035년까지 미국 인구의 45.1%에 해당하는 1억 3천만 명 이상의 성인이 CVD를 앓을 것으로 예상되고 있습니다. 이러한 CVD 환자의 급증은 스타틴, 베타차단제, 항응고제, 항혈전제, 강압제 등 장기 투약 관리가 필요한 환자 증가로 이어집니다.

미국암협회에 따르면 2022년 국내에서는 190만 명이 새로 암 진단을 받고 61만 명이 사망할 것으로 예측됩니다. 암 환자가 증가함에 따라 혁신적인 치료 옵션에 대한 수요가 증가하고 있습니다. 치료용 백신은 기존 치료법을 대체할 수 있는 유망 대안이 될 수 있습니다. 2010년 FDA의 승인을 받은 프로벤지(sipuleucel-T)는 암 치료를 위해 승인되어 처방된 최초의 치료용 암 백신입니다. 또한 종양학, 면역학, 유전자 치료의 발전으로 다양한 암과 자가면역질환에 대한 치료 옵션이 확대되고 있습니다. 이러한 발전에도 불구하고 처방약 지출은 계속 증가하고 있습니다. 미국 의료 시스템 약사 협회에 따르면 2024년 미국은 처방약에 8,059억 달러를 지출할 것으로 예상되며, 이는 전년 대비 10.2% 증가한 수치입니다. 이러한 증가는 이러한 의약품에 대한 수요 증가와 고가의 새로운 치료법의 도입으로 인한 것입니다. 또한 미국인의 79%는 처방약 가격이 '불합리하다'고 생각하고 있으며, 70%는 처방약 가격 인하를 헬스케어의 최우선 과제로 꼽고 있습니다. 랜드코퍼레이션에 따르면 미국의 처방약 가격은 경제협력개발기구(OECD) 32개국 평균의 2.56배, 오리지널 의약품은 3.44배에 달할 전망입니다. 이러한 비용에 대응하기 위해 메디케어의 약가 협상을 목적으로 하는 인플레이션 감소법(IRA)이 도입되었습니다. 2024년, 미국 정부는 IRA 2022에 따라 첫 10개 품목의 약가를 결정하며 큰 전환점을 맞이했습니다. 수개월에 걸친 제약사와의 협상 결과, 스텔라라, 자디앙스 등의 약값이 38%에서 79%까지 인하되었습니다. 이러한 변화로 2026년까지 납세자는 60억 달러, 환자는 15억 달러의 비용을 절감할 수 있을 것으로 예측됩니다.

지출은 계속 증가하고 있지만, 미국인들이 보다 저렴한 가격으로 의약품을 구입할 수 있도록 하기 위한 입법적 노력이 진행되고 있습니다. 2025년 5월, 도널드 트럼프 대통령은 "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"라는 제목의 대통령령에 서명했습니다. 트럼프 대통령은 이번 행정명령의 목적은 미국인과 납세자가 처방약에 대해 지불하는 가격을 동등한 국가에서 지불하는 가격에 맞추기 위한 것이라고 밝혔습니다. 이번 조치로 약값이 최소 50% 이상 인하될 것으로 예상되며, 트럼프 대통령의 2020년 최혜국 대우 모델의 보다 적극적인 버전이라고 할 수 있습니다.

맞춤형 의료와 정밀의료의 성장은 향후 시장 기회를 가져올 것입니다.

맞춤형 의료와 정밀의료는 기술 발전, 유전체학에 대한 이해의 심화, 개인 맞춤형 치료 접근법의 채택이 증가하고 있습니다. 맞춤형 의료는 개인의 유전적, 환경적, 생활습관적 요인에 따라 맞춤형 의료를 제공하는 것으로, 보다 효과적이고 타겟팅된 치료를 가능하게 합니다. HER2 양성 유방암 치료제인 트라스투주맙(허셉틴)과 같은 표적 암 치료제의 개발은 유전자 프로파일링이 특정 치료제로부터 가장 큰 혜택을 받을 수 있는 환자를 식별하고, 효능을 향상시키며, 부작용을 줄일 수 있다는 것을 잘 보여줍니다. 동반진단약의 채택이 진행됨에 따라 유전자 검사가 일상적인 임상에 접목되어 약물의 효과와 안전성이 높아질 것으로 예측됩니다.

인공지능(AI), 빅데이터 분석 등 기술의 발전은 맞춤형 의료의 발견을 가속화하고 있습니다. AI 기반 알고리즘은 방대한 데이터세트를 분석하여 약물에 대한 개별 반응을 예측하고, 새로운 치료 표적을 식별하며, 약물 개발 프로세스를 간소화합니다. 예를 들어 Tempus와 같은 기업은 AI를 활용하여 환자의 유전자 프로파일에 따라 암 치료를 조정하여 보다 정확하고 효과적인 개입을 제공합니다. 따라서 기술 혁신과 보다 효과적이고 안전한 환자 중심적인 치료법의 임상적 채택이 증가함에 따라 전 세계에서 의료 서비스 제공과 결과를 변화시키고 향후 수년간 시장 성장에 기여할 것으로 예측됩니다.

미국 식품의약국, 국립암연구소, 유럽의약품청, 중앙의약품표준관리기구, Our World in data 등은 처방약 시장 보고서 작성시 참고한 1차 및 2차 정보 중 하나입니다.

처방약시장 - 주요 시장 역학
시장 성장 촉진요인
- 만성질환의 유병률 증가
- 혁신적 및 특수한 의약품의 개발과 채택
시장 성장 억제요인
- 약가의 상승과 적정 가격 문제
시장 기회
- 시장 기업의 전략적 구상
향후 동향
- 맞춤형 의료와 정밀의료의 성장
촉진요인과 억제요인의 영향

제6장 처방약시장 - 세계 시장 분석

처방약 시장 매출, 2021-2031년
처방약 시장 예측 분석

제7장 처방약시장 분석 - 제품 유형별

브랜드 의약품
제네릭 의약품

제8장 처방약 시장 분석 - 약제 유형별

저분자 의약품
생물제제와 바이오시밀러

제9장 처방약 시장 분석 - 치료 영역별

암영역
심혈관질환
신경질환
대사성 질환
호흡기질환
면역학
기타

제10장 처방약시장 분석 - 투여 경로별

경구제
주사제
외용약
기타

제11장 처방약 시장 분석 - 유통 채널별

병원 약국
소매 약국
온라인 약국

제12장 처방약시장 분석 - 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽 국가
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카 국가
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제13장 경쟁 구도

주요 기업에 의한 히트맵 분석
기업의 포지셔닝과 집중도

제14장 업계 상황

처방약시장에서 성장 전략
유기적 성장 전략
무기적 성장 전략

제15장 기업 개요

Johnson & Johnson
Pfizer Inc
Merck & Co Inc
Eli Lilly and Co
ESTEVE
AstraZeneca Plc
Sanofi SA
GSK Plc
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc
Teva Pharmaceutical Industries Ltd

제16장 부록

KSA 25.08.07

According to our new research study on "Prescription Drugs Market Forecast to 2031 -Global Analysis - by Product Type, Drug Type, Route Of Administration, Therapeutic Area, And Distribution Channel," the market is anticipated to grow from US$ 1,440.79 billion in 2024 and is projected to reach US$ 2,350.12 billion by 2031; it is expected to register a CAGR of 7.3% from 2025 to 2031. The prescription drugs market growth is attributed to the increasing prevalence of chronic disorders and development and adoption of innovative and specialty drugs.

Prescription drugs are medications that legally require a medical prescription from a licensed healthcare professional. They are regulated because they can have significant effects on the body, require monitoring for safety, or have potential for misuse.

The prescription drugs market in North America is segmented into the US, Canada, and Mexico. North America is likely to capture a significant share of the global market. One of the primary drivers is the region's aging population. As the baby boomer generation grows older, the prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer has increased, thereby boosting the demand for prescription medications.

Advancements in pharmaceutical research and biotechnology have also played a critical role. Innovations in drug development, including biologics and personalized medicine, have expanded treatment options, enhancing efficacy and safety. The introduction of novel therapies for previously untreatable conditions has further propelled market growth.

Another major contributor is the strong healthcare infrastructure in North America, supported by substantial investments in healthcare facilities, insurance coverage, and pharmaceutical distribution networks. The widespread availability of healthcare services and better patient awareness about disease management have increased prescription drug consumption. Additionally, regulatory support from agencies such as the US Food and Drug Administration (FDA) facilitates quicker approval processes for innovative drugs, enabling faster market entry. Furthermore, government initiatives aimed at expanding healthcare coverage, such as the Affordable Care Act in the US, have increased access to prescription drugs for a broader population.

Also, the rise in lifestyle-related diseases and increased prevalence of mental health disorders have created a sustained demand for therapeutic drugs. The COVID-19 pandemic also emphasized the importance of pharmaceutical interventions, accelerating investments in drug development and distribution.

In North America, the US holds a significant share of the prescription drugs market. Chronic conditions such as cancer, heart disease, and diabetes are contributing to the rising demand for prescription medications. Heart disease remains the leading cause of death in the US, with nearly one million Americans annually succumbing to cardiovascular disease (CVD). According to the American Heart Association, nearly half of all adults in the US have some type of CVD, and it is estimated that the number of adults suffering from heart failure is projected to increase by 2035. Over 130 million adults, i.e., 45.1% of the US population, are expected to report some form of CVD by 2035. This surge in CVD cases leads to a higher number of patients requiring long-term medication management, including statins, beta-blockers, anticoagulants, and antihypertensive drugs.

According to the American Cancer Society, in 2022, ~1.9 million new cases of cancer were diagnosed in the country, and it caused ~0.61 million deaths. With the increasing cases of cancer, the demand for innovative treatment options is rising. Therapeutic vaccines offer promising alternatives to traditional therapies. Provenge (sipuleucel-T), approved by the FDA in 2010, is the first therapeutic cancer vaccine to receive approval and prescribed medication for cancer treatment. Additionally, advancements in oncology, immunology, and gene therapies are expanding treatment options for various cancers and autoimmune diseases. Despite these advancements, prescription drug spending continues to rise. According to the American Society of Health-System Pharmacists, in 2024, Americans spent US$ 805.9 billion on prescription drugs, a 10.2% increase from the previous year. This increase is attributed to higher demand for these medications and the introduction of new, expensive treatments. Additionally, 79% of Americans believe that prescription drug prices are "unreasonable," while 70% consider reducing these costs to be their top healthcare priority. According to the Rand Corporation, on average, prescription drug prices in the US are 2.56 times higher than those in 32 other Organization for Economic Co-operation and Development (OECD) countries, with brand-name medications costing 3.44 times more. To address these costs, the Inflation Reduction Act (IRA), which aims to negotiate drug prices for Medicare, was introduced. In 2024, the US government finalized prices for the first ten drugs under the IRA 2022, marking a significant milestone. After months of negotiations with drug manufacturers, prices for medications such as Stelara and Jardiance have reduced by 38% to 79%. These changes are anticipated to save taxpayers US$6 billion by 2026 and provide US$1.5 billion in savings for patients.

While spending continues to rise, legislative efforts are underway to make medications more affordable for Americans. In May 2025, President Donald Trump signed an executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients." Trump stated that the order aims to align the prices Americans and taxpayers pay for prescription drugs with those paid in comparable countries. The measure is expected to cut drug prices by at least 50% and is characterized as a more aggressive version of Trump's 2020 Most Favored Nation model.

Growth of Personalized and Precision Medicine to Provide Market Opportunities in Future

Personalized and precision medicine is experiencing growing technological advancements, increasing understanding of genomics, and rising adoption of personalized therapeutic approaches. Personalized medicine involves customizing healthcare based on individual genetic, environmental, and lifestyle factors, allowing for more effective and targeted treatments. The development of targeted cancer therapies such as trastuzumab (Herceptin) for HER2-positive breast cancer exemplifies how genetic profiling can identify patients who will benefit most from specific treatments, improving efficacy and reducing adverse effects. The increasing adoption of companion diagnostics is expected to integrate genetic testing into routine clinical practice, enhancing drug efficacy and safety.

Technological advancements such as artificial intelligence (AI) and big data analytics are accelerating discoveries in personalized medicine. AI-driven algorithms analyze vast datasets to predict individual responses to drugs, identify new therapeutic targets, and streamline drug development processes. For instance, companies such as Tempus are harnessing AI to tailor cancer treatments based on patients' genetic profiles, offering more precise and effective interventions. Therefore, technological innovations and increasing clinical adoption of more effective, safer, and patient-centric therapies, transforming healthcare delivery and outcomes globally, are expected to contribute to the market growth in coming years.

The US Food and Drug Administration, National Cancer Institute, European Medicines Agency, Central Drugs Standard Control Organization, and Our World in data are among the primary and secondary sources referred to while preparing the prescription drugs market report.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Prescription Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Prescription Drugs Market - Key Market Dynamics

5.1 Prescription Drugs Market - Key Market Dynamics
5.2 Market Drivers:
- 5.2.1 Increasing Prevalence of Chronic Disorders
- 5.2.2 Development and Adoption of Innovative and Specialty Drugs
5.3 Market Restraints
- 5.3.1 High Drug Prices and Affordability Issues
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
- 5.5.1 Growth of Personalized and Precision Medicine
5.6 Impact of Drivers and Restraints:

6. Prescription Drugs Market - Global Market Analysis

6.1 Prescription Drugs Market Revenue (US$ Billion), 2021-2031
6.2 Prescription Drugs Market Forecast Analysis

7. Prescription Drugs Market Analysis - by Product Type

7.1 Branded
- 7.1.1 Overview
- 7.1.2 Branded: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
7.2 Generics
- 7.2.1 Overview
- 7.2.2 Generics: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

8. Prescription Drugs Market Analysis - by Drug Type

8.1 Small Molecule
- 8.1.1 Overview
- 8.1.2 Small Molecule: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
8.2 Biologics and Biosimilar
- 8.2.1 Overview
- 8.2.2 Biologics and Biosimilar: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

9. Prescription Drugs Market Analysis - by Therapeutic Area

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Oncology: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.2 Cardiovascular Diseases
- 9.2.1 Overview
- 9.2.2 Cardiovascular Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.3 Neurological Diseases
- 9.3.1 Overview
- 9.3.2 Neurological Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.4 Metabolic Diseases
- 9.4.1 Overview
- 9.4.2 Metabolic Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.5 Respiratory Diseases
- 9.5.1 Overview
- 9.5.2 Respiratory Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.6 Immunology
- 9.6.1 Overview
- 9.6.2 Immunology: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.7 Others
- 9.7.1 Overview
- 9.7.2 Others: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

10. Prescription Drugs Market Analysis - by Route Of Administration

10.1 Oral
- 10.1.1 Overview
- 10.1.2 Oral: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
10.2 Injectable
- 10.2.1 Overview
- 10.2.2 Injectable: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
10.3 Topical
- 10.3.1 Overview
- 10.3.2 Topical: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

11. Prescription Drugs Market Analysis - by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Hospital Pharmacies: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
11.2 Retail Pharmacies
- 11.2.1 Overview
- 11.2.2 Retail Pharmacies: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
11.3 Online Pharmacies
- 11.3.1 Overview
- 11.3.2 Online Pharmacies: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

12. Prescription Drugs Market - Geographical Analysis

12.1 North America
- 12.1.1 North America Prescription Drugs Market Overview
- 12.1.2 North America: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.1.2.1 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.1.2.2 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.1.2.3 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.1.2.4 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.1.2.5 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.1.3 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.1.3.1 United States: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.1.3.1.1 United States: Prescription Drugs Market Breakdown, by Product Type
    - 12.1.3.1.2 United States: Prescription Drugs Market Breakdown, by Drug Type
    - 12.1.3.1.3 United States: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.1.3.1.4 United States: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.1.3.1.5 United States: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.1.3.2 Canada: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.1.3.2.1 Canada: Prescription Drugs Market Breakdown, by Product Type
    - 12.1.3.2.2 Canada: Prescription Drugs Market Breakdown, by Drug Type
    - 12.1.3.2.3 Canada: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.1.3.2.4 Canada: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.1.3.2.5 Canada: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.1.3.3 Mexico: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.1.3.3.1 Mexico: Prescription Drugs Market Breakdown, by Product Type
    - 12.1.3.3.2 Mexico: Prescription Drugs Market Breakdown, by Drug Type
    - 12.1.3.3.3 Mexico: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.1.3.3.4 Mexico: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.1.3.3.5 Mexico: Prescription Drugs Market Breakdown, by Distribution Channel
12.2 Europe
- 12.2.1 Europe Prescription Drugs Market Overview
- 12.2.2 Europe: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.2.2.1 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.2.2.2 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.2.2.3 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.2.2.4 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.2.2.5 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.2.3 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.2.3.1 Germany: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.1.1 Germany: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.1.2 Germany: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.1.3 Germany: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.1.4 Germany: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.1.5 Germany: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.2 United Kingdom: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.2.1 United Kingdom: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.2.2 United Kingdom: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.2.3 United Kingdom: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.2.4 United Kingdom: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.2.5 United Kingdom: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.3 France: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.3.1 France: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.3.2 France: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.3.3 France: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.3.4 France: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.3.5 France: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.4 Italy: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.4.1 Italy: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.4.2 Italy: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.4.3 Italy: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.4.4 Italy: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.4.5 Italy: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.5 Spain: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.5.1 Spain: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.5.2 Spain: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.5.3 Spain: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.5.4 Spain: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.5.5 Spain: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.6 Rest of Europe: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.6.1 Rest of Europe: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.6.2 Rest of Europe: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.6.3 Rest of Europe: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.6.4 Rest of Europe: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.6.5 Rest of Europe: Prescription Drugs Market Breakdown, by Distribution Channel
12.3 Asia Pacific
- 12.3.1 Asia Pacific Prescription Drugs Market Overview
- 12.3.2 Asia Pacific: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.3.2.1 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.3.2.2 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.3.2.3 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.3.2.4 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.3.2.5 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.3.3 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.3.3.1 China: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.1.1 China: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.1.2 China: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.1.3 China: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.1.4 China: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.1.5 China: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.2 Japan: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.2.1 Japan: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.2.2 Japan: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.2.3 Japan: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.2.4 Japan: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.2.5 Japan: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.3 India: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.3.1 India: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.3.2 India: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.3.3 India: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.3.4 India: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.3.5 India: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.4 Australia: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.4.1 Australia: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.4.2 Australia: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.4.3 Australia: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.4.4 Australia: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.4.5 Australia: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.5 South Korea: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.5.1 South Korea: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.5.2 South Korea: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.5.3 South Korea: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.5.4 South Korea: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.5.5 South Korea: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.6 Rest of APAC: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.6.1 Rest of APAC: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.6.2 Rest of APAC: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.6.3 Rest of APAC: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.6.4 Rest of APAC: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.6.5 Rest of APAC: Prescription Drugs Market Breakdown, by Distribution Channel
12.4 Middle East and Africa
- 12.4.1 Middle East and Africa Prescription Drugs Market Overview
- 12.4.2 Middle East and Africa: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.4.2.1 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.4.2.2 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.4.2.3 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.4.2.4 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.4.2.5 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.4.3 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.4.3.1 Saudi Arabia: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.1.1 Saudi Arabia: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.1.2 Saudi Arabia: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.1.3 Saudi Arabia: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.1.4 Saudi Arabia: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.1.5 Saudi Arabia: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.4.3.2 South Africa: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.2.1 South Africa: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.2.2 South Africa: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.2.3 South Africa: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.2.4 South Africa: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.2.5 South Africa: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.4.3.3 United Arab Emirates: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.3.1 United Arab Emirates: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.3.2 United Arab Emirates: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.3.3 United Arab Emirates: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.3.4 United Arab Emirates: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.3.5 United Arab Emirates: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.4.3.4 Rest of Middle East and Africa: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.4.1 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.4.2 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.4.3 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.4.4 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.4.5 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Distribution Channel
12.5 South and Central America
- 12.5.1 South and Central America Prescription Drugs Market Overview
- 12.5.2 South and Central America: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.5.2.1 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.5.2.2 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.5.2.3 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.5.2.4 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.5.2.5 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.5.3 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.5.3.1 Brazil: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.5.3.1.1 Brazil: Prescription Drugs Market Breakdown, by Product Type
    - 12.5.3.1.2 Brazil: Prescription Drugs Market Breakdown, by Drug Type
    - 12.5.3.1.3 Brazil: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.5.3.1.4 Brazil: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.5.3.1.5 Brazil: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.5.3.2 Argentina: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.5.3.2.1 Argentina: Prescription Drugs Market Breakdown, by Product Type
    - 12.5.3.2.2 Argentina: Prescription Drugs Market Breakdown, by Drug Type
    - 12.5.3.2.3 Argentina: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.5.3.2.4 Argentina: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.5.3.2.5 Argentina: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.5.3.3 Rest of South and Central America: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.5.3.3.1 Rest of South and Central America: Prescription Drugs Market Breakdown, by Product Type
    - 12.5.3.3.2 Rest of South and Central America: Prescription Drugs Market Breakdown, by Drug Type
    - 12.5.3.3.3 Rest of South and Central America: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.5.3.3.4 Rest of South and Central America: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.5.3.3.5 Rest of South and Central America: Prescription Drugs Market Breakdown, by Distribution Channel

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning & Concentration

14. Industry Landscape

14.1 Overview
14.2 Growth Strategies in the Prescription Drugs Market
14.3 Organic Growth Strategies
- 14.3.1 Overview
14.4 Inorganic Growth Strategies
- 14.4.1 Overview

15. Company Profiles

15.1 Johnson & Johnson
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Pfizer Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Merck & Co Inc
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Eli Lilly and Co
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 ESTEVE
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 AstraZeneca Plc
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Sanofi SA
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 GSK Plc
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 F. Hoffmann-La Roche Ltd
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 Novartis AG
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments
15.11 AbbVie Inc
- 15.11.1 Key Facts
- 15.11.2 Business Description
- 15.11.3 Products and Services
- 15.11.4 Financial Overview
- 15.11.5 SWOT Analysis
- 15.11.6 Key Developments
15.12 Teva Pharmaceutical Industries Ltd
- 15.12.1 Key Facts
- 15.12.2 Business Description
- 15.12.3 Products and Services
- 15.12.4 Financial Overview
- 15.12.5 SWOT Analysis
- 15.12.6 Key Developments

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms